ArticleAdvances in therapy2025
Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for Meralgia Paresthetica: A Description of a Novel Technique.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.Advances in therapy · 2026Article
- Clinical Outcomes of Ultrasound-Guided IPACK Block for Posterior Knee Pain in Advanced Osteoarthritis: A Multicenter Prospective Single-Arm Study.Journal of clinical medicine · 2026Article
- Meralgia paresthetica: from qualitative ultrasound assessment to quantitative multimodality imaging.Journal of ultrasonography · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meralgia paresthetica (MP) is neuropathic pain in the anterolateral thigh, most often caused by compression or injury to the lateral femoral cutaneous nerve (LFCN). Conservative treatments include weight loss, avoidance of compressive clothing, medical management with anti-inflammatory and neuropathic agents, and corticosteroid injections. For patients with MP refractory to these measures, radiofrequency ablation (RFA) is a minimally invasive option that may provide pain relief. This article introduces a novel ultrasound-guided continuous RFA technique designed to create a controlled thermal lesion of the LFCN, along with preliminary clinical outcomes. Pronounced anatomic variation of the LFCN at the anterior superior iliac spine makes real-time imaging essential for procedural accuracy, with ultrasound offering consistent nerve visualization and precise needle placement. Continuous RFA has demonstrated substantial and durable reductions in VAS scores, whereas pulsed RFA provides shorter-term relief with a favorable safety profile, and cooled RFA produces broader lesions that may help address anatomical variability, although supporting evidence is limited. Overall, RFA can be an effective treatment for MP refractory to conservative therapy, with optimal results dependent on detailed anatomical knowledge and accurate image guidance, particularly when using the novel continuous RFA approach described in this study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.